

1 **Quantifying SARS-CoV-2 infection risk within the Google/Apple exposure notification**  
2 **framework to inform quarantine recommendations**

3  
4

5 Amanda M. Wilson, PhD<sup>1</sup>; Nathan Aviles<sup>2</sup>, James I. Petrie<sup>3</sup>, Paloma I. Beamer, PhD<sup>1</sup>; Zsombor  
6 Szabo<sup>3</sup>, Michelle Xie<sup>3</sup>, Janet McIllece<sup>4</sup>, Yijie Chen<sup>5</sup>, Young-Jun Son, PhD<sup>5</sup>; Sameer Halai<sup>3</sup>,  
7 Tina White<sup>3</sup>, Kacey C. Ernst, PhD<sup>1</sup>; Joanna Masel, DPhil<sup>6,7</sup>

8

9 <sup>1</sup> Mel & Enid Zuckerman College of Public Health, University of Arizona, 1295 N Martin Ave,  
10 Tucson, AZ 85724, USA

11 <sup>2</sup> Graduate Interdisciplinary Program in Statistics, University of Arizona, 617 N. Santa Rita Ave.  
12 University of Arizona, Tucson, AZ 85721, USA

13 <sup>3</sup> Covid Watch, 433 S Stratford Drive, Tucson, AZ 85716, USA

14 <sup>4</sup> World Wide Technology, 1 World Wide Way, St. Louis, MO 63146, USA

15 <sup>5</sup> Systems and Industrial Engineering, University of Arizona, 1127 E. James E. Rogers Way,  
16 CIMS Lab, 85721, USA

17 <sup>6</sup> Ecology & Evolutionary Biology, University of Arizona, 1041 E Lowell St., Tucson AZ 85721

18 \* corresponding author [masel@email.arizona.edu](mailto:masel@email.arizona.edu) 520 626 9888

19

20 ORCID: AMW 0000-0003-3259-8169, NA 0000-0001-9998-4406, JIP 0000-0001-7959-7687,  
21 PIB 0000-0001-5287-2183, ZS 0000-0002-3653-1378, MX 0000-0001-9512-3684, YC 0000-  
22 0001-5316-4103, YS 0000-0002-4004-2155, KCE 000-0002-3346-7788 JM 0000-0002-7398-  
23 2127

24

25

26 **Abstract**

27

28 **Background:** Most Bluetooth-based exposure notification apps use three binary classifications  
29 to recommend quarantine following SARS-CoV-2 exposure: a window of infectiousness in the  
30 transmitter,  $\geq 15$  minutes duration, and Bluetooth attenuation below a threshold. However,  
31 Bluetooth attenuation is not a reliable measure of distance, and infection risk is not a binary  
32 function of distance, nor duration, nor timing.

33

34 **Methods:** We model uncertainty in the shape and orientation of an exhaled virus-containing  
35 plume and in inhalation parameters, and measure uncertainty in distance as a function of  
36 Bluetooth attenuation. We calculate expected dose by combining this with estimated  
37 infectiousness based on timing relative to symptom onset. We calibrate an exponential dose-  
38 response curve on the basis of the infection probabilities of household contacts. The conditional  
39 probability of current or future infectiousness, conditioned on how long post-exposure an  
40 exposed individual has been free of symptoms, decreases during quarantine, with shape  
41 determined by the distribution of incubation periods, proportion of asymptomatic cases, and  
42 distribution of asymptomatic shedding durations. It can be adjusted for negative test results  
43 using Bayes Theorem.

44

45 **Findings:** We capture a 10-fold range of risk using 6 infectiousness values, 11-fold range using  
46 3 Bluetooth attenuation bins, ~6-fold range from exposure duration given the 30 minute duration  
47 cap imposed by the Google/Apple v1.1, and ~11-fold between the beginning and end of 14 day  
48 quarantine. Imposing a consistent risk threshold for the probability of infection can recommend  
49 quarantine with weaker Bluetooth signal, even when not recommended for the entirety of the  
50 infectious period.

51

52 **Interpretation:** The Covid-Watch app is currently programmed either to use a threshold on  
53 initial infection risk to determine 14-day quarantine onset, or on the conditional probability of  
54 current and future infectiousness conditions to determine both quarantine and duration. Either  
55 threshold can be set by public health authorities.

56

57 **Funding:** University of Arizona

58

59 **Research in Context:**

60

61 **Evidence before this study**

62

63 Epidemiological models suggest a benefit from smartphone-based automatic notification of  
64 exposure to Covid-19 infected individuals. Google and Apple have rolled out a privacy-  
65 preserving API with which apps can offer such notifications based on the degree of Bluetooth  
66 attenuation of a signal issued by an infected individual, its duration, and its timing relative to  
67 symptom onset in and test date for that infected individual. Apps deployed so far have focused  
68 on approximating close contact definitions of 15 minutes and a given distance such as 1 meter  
69 or 2 meters. However, Bluetooth attenuation is not a reliable measure of distance, and infection  
70 risk is not a binary function of distance, nor duration, nor timing.

71

72 **Added value of this study**

73

74 We integrate all sources of information (including our own new experiments on the relationship  
75 between distance and Bluetooth attenuation) to provide a measure of infection risk that is as  
76 accurate as possible given the data on exposure that is available to an app based on the  
77 Google/Apple system. We also provide a method to calculate the probability of current or future  
78 infectiousness, which is a function not only of initial infection risk, but also of the number of  
79 symptom-free days since exposure, and any negative test results.

80

81 **Implications of all available evidence**

82

83 Our risk scoring system can guide quarantine recommendations in exposure notification apps,  
84 targeting them to individuals who are the most likely to be infected. It can also recommend  
85 release from quarantine on the day that the probability of current or future infectiousness falls  
86 below a threshold, leading to different quarantine durations for different individuals.

87

88

## 89 **Background**

90

91 Manual contact tracing followed by quarantine of known contacts is a critical method for  
92 containing or mitigating the spread of communicable diseases. It is, however, extremely  
93 resource and time-intensive and relies on case recall of contacts. New technologies can  
94 supplement this approach.<sup>1</sup> Manual contact tracing can be effective for COVID-19<sup>2-4</sup>, however,  
95 a significant challenge is the extremely short window of time between an infected individual  
96 presenting for testing and the contacts that they infected beginning to shed infectious virus.<sup>5,6</sup>  
97 Automatic exposure notification approaches based on Bluetooth proximity have the potential to  
98 achieve many of the benefits of contact tracing, while also providing more rapid notification,  
99 greater privacy<sup>7,8</sup>, more objective recall of contacts including those whose identity is unknown to  
100 the case, and greater scalability.<sup>5,9</sup> The two approaches of contact tracing and exposure  
101 notifications are complementary and may directly interact e.g. when those receiving digital  
102 exposure notifications are referred to human contact tracers for the information and support  
103 needed for quarantine adherence and further investigation.<sup>10</sup>

104

105 Apps have access to data on timing, duration, and Bluetooth attenuation. Determining the  
106 threshold for entering quarantine based on probability of infection should yield better results  
107 than from combining three binary thresholds for duration, distance, and the infectious period of  
108 the transmitter. A threshold for exiting quarantine based on the conditional probability of current  
109 or future infectiousness could also be used. Both would help optimize the reduction in disease  
110 transmission per day of quarantine recommended.

111


112 Here we lay out a framework for doing so using the decentralized protocol of the Google/Apple  
113 Exposure Notification (GAEN) Application Programming Interface (API). When a user reports  
114 positive infection status, the GAEN v1.1 framework (Figure 1) allows apps to assign a  
115 “Transmission Risk Level” to each day that they might have been shedding, and to  
116 communicate this level to the receiver’s phone via a Temporary Exposure Key (TEK). On the  
117 receiver’s device, the GAEN framework records Bluetooth attenuation as a rough estimate of  
118 distance, and the duration of exposure.

119

120 The risk of infection depends on viral dose,<sup>11</sup> which in turn depends on the shedding rate of the  
121 infected individual, and on the duration and distance of the interaction. As days go by without  
122 onset of symptoms, the probability of future infectiousness decreases, because the probability is  
123 conditioned on lack of symptoms for an increasing stretch of time. We parameterize calculations  
124 of both probabilities using both past literature and new experiments and illustrate what different  
125 risk thresholds imply for quarantine recommendations. We are piloting and evaluating the Covid  
126 Watch app using portions of this scheme on the campus of the University of Arizona.

127

128



129  
130

**Figure 1.** Assessment of the probability of infection following a single exposure. The calibration work is reported in this manuscript, and the procedures on the Transmitter's and Receiver's phones are part of the Covid Watch app.

131  
132  
133  
134

## Methods

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

The overall approach to calculating infection risk is summarized in Figure 1. Parameter values and their descriptions and sources are summarized in Supplementary Table 1 for calculations performed by the app and in Supplementary Table 2 for parameters we used during calibration.

The GAEN v1.1 framework records exposure durations only up to 30 minutes, in order to protect anonymity of COVID-positive patients by limiting the risk that users will be able to guess the source of their exposure, while still meeting contact definitions that invoke minimum exposure duration of 15 minutes. Durations can be recorded separately within three bins of attenuation, thus allowing a total of 90 minutes if the attenuation varies in the necessary manner over the exposure. We calculate a weighted sum of the three durations, using the weights to capture the differences in expected dose (number of inhaled particles over an exposure time). Note that GAEN v1.5 lifts the duration cap but restricts our ability to record levels of infectiousness. We focus here on GAEN v1.1, but our scheme can be adapted for later versions.

We measured Bluetooth attenuation under GAEN v1.1 for a range of distances, phones, and scenarios of possible signal interference with the potential to affect the attenuation – distance

154 relationship (Supplementary Materials Section 1).<sup>12</sup> We rebalanced this dataset to form a  
155 pseudo dataset that is more representative of the distribution of barriers and scenarios in the  
156 real world (Supplementary Materials Section 1).

157  
158 From this pseudo dataset, we first sample a datapoint that falls within the attenuation bin in  
159 question. If this is a zero-risk barrier scenario, we assign an infection risk of 0. Otherwise, we  
160 record the distance  $\rho$  in meters. Note that our method is not based on mapping thresholds in  
161 distance to thresholds in Bluetooth attenuation, but instead on resampling from the probability  
162 distribution of distance as a function of attenuation.

163  
164 We feed this distance into a microbial exposure model that estimates the airborne spread of  
165 viral particles from an emitter's mouth following a Gaussian plume formation, and their  
166 subsequent inhalation by contacts (Supplementary Materials Sections 2 and 3). We use a  
167 Monte Carlo approach to sample angle, exhalation rate of the transmitter, cross-section of the  
168 transmitter's open mouth, and inhalation rate of the exposed individual, to obtain a mean  
169 dose/time for that attenuation bin. For distances  $\leq 1$  meter, we assume face to face interactions,  
170 consistent with distances measured for "interpersonal" interactions.<sup>13</sup> We choose thresholds  
171 between attenuation bins, and relative risks for time spent in each bin (Supplementary Materials  
172 Section 4).

173  
174 We use an exponential dose-response curve, which is derived from the assumption that each  
175 host is susceptible and that each virus has an independent probability of survival and  
176 subsequent initialization of infection.<sup>11</sup> In our case, this probability  $k$ , multiplied by a constant  $C$   
177 to convert from arbitrary units to number of viruses, sets the parameter  $\lambda = kC$  in the equation  
178

$$179 \quad P(\text{infection}) = 1 - e^{-\lambda D},$$

180  
181 where expected dose  $D$  comes from a shedding rate multiplied by a weighted sum of time spent  
182 within 3 attenuation ranges. An exponential dose-response curve is superior to the approximate  
183 beta-Poisson for some other viruses (<http://qmrwiki.org/content/recommended-best-fit-parameters>,  
184 accessed 09/07/2020). These viruses include adenovirus, enterovirus, poliovirus,  
185 and SARS-CoV-1.


186  
187 Our weighted sum of durations and our estimates of shedding rates  $S$  in the Results are both in  
188 arbitrary units. We therefore fit  $\lambda$  to obtain infection probabilities that are compatible with  
189 household spread. Asymptomatic infection and low test sensitivity can both deflate estimated  
190 household infection risks, while indirect chains of infection via a third household member can  
191 inflate them. A meta-analysis by Curmei et al.<sup>14</sup> attempted to correct for these complications and  
192 estimated a secondary attack rate of household contacts of 30%. We assumed exposure is  
193 equivalent to 8 hours with the maximum shedding rate in the lowest attenuation and calculated  
194  $\lambda$  for this dose that would result in a 30% infection risk.

195  
196 Our scheme can be used either to 1) set a threshold on the initial probability of infection to  
197 trigger 14-day quarantine, or 2) set a threshold for the probability of current or future  
198 infectiousness to determine both who should quarantine and for how long. Our method for  
199 calculating the probability of current or future infectiousness, conditioned on lack of symptoms  
200 so far and incorporating the possibility of asymptomatic infection, is described in Supplementary  
201 Materials Section 5. The parameters used are summarized in Table 1. This method can be  
202 extended to inform the timing of testing and the effect of a negative test result on a  
203 recommended duration of quarantine (Supplementary Materials Section 6). Note that strictly

204 speaking when using this latter threshold, our “quarantine” recommendations are, through their  
205 treatment of the possibility of undiagnosed asymptomatic infection, a combination of quarantine  
206 and isolation.

207  
208 Our scheme, by expressing exposures in terms of probabilities of infection and infectiousness,  
209 naturally lends itself to combining risks over multiple exposures (Supplementary Materials  
210 Section 7).

211



212 **Figure 2.** Expected dose and corresponding probability of infection for a 30-minute exposure,  
213 estimated using our Monte Carlo procedure as a function of distance from an infected individual.  
214 The discontinuity at 1 meter indicates our assumption that this distance threshold indicates face-  
215 to-face interaction. Faded points show doses and infection risks that would be estimated if a  
216 face-to-face or non-face-to-face interaction assumption were consistent across distances. The  
217 bolded points indicate what we assumed in our framework. Note that Bluetooth information likely  
218 contains more risk information regarding whether an interaction was face-to-face than it does  
219 about risk as a function of the distance at which either a face-to-face or a non-face-to-face  
220 interaction takes place. The WHO close contact definition invoking 1 meter also invokes face-to-  
221 face interaction.<sup>15</sup> The same is true, only with 2 meters, for European guidance (available at  
222 <https://www.ecdc.europa.eu/en/covid-19-contact-tracing-public-health-management>, accessed  
223 on 7/1/2020).<sup>16</sup> The Centers for Disease Control and Prevention (CDC)’s definition departs from  
224 this in omitting reference to face-to-face when referring to interactions occurring within 6 feet  
225 (available at [https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html)  
226 [recommenations.html](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html), accessed on 7/1/2020).<sup>17</sup>

227  
228  
229  
230  
231  
232

## 233 Results

234

235 Our Gaussian plume model of microbial exposure produces the relationship between distance  
236 and infection risk shown in Figure 2. Training on both this and our distance-attenuation  
237 measurements (as summarized in Methods), we chose the 3 attenuation bins of  $\leq 50$ dB (close  
238 range), 50-70dB (medium range), and  $>70$  dB (far range), with weights 2.15, 0.79, and 0.19,  
239 respectively. Using these weights, we calibrate  $\lambda = 3.50 \times 10^{-6}$  (see Methods) to obtain an  
240 infection probability of 0.30 for household contacts. Note that the best way to calibrate both  
241 weights and  $\lambda$  would be after the app is rolled out, with manual contact tracers compiling  
242 exposure characteristics and relating them to the rate of subsequent infection. While Eq. 5  
243 calculates the function of an expectation rather than an expectation of a function, treating  
244 variance in dose amounts to using an “effective” value of  $\lambda$  (Supplementary Materials Section  
245 8).

246

247 Bluetooth attenuation thus only distinguishes a 2.7-fold difference in dose and hence risk  
248 between close and medium range, and only 11-fold between close and far range. In contrast,  
249 informed both by TCID50 data<sup>18</sup> and by epidemiological evidence<sup>19</sup>, we assign a 10-fold higher  
250 risk to exposures to individuals during peak shedding than during the margins of the infectious  
251 period (Supplementary Materials Section 9, illustrated in Figure 3A). The magnitude of shedding  
252 (transmission risk value) has received less attention than attenuation and exposure duration and  
253 is not to our knowledge widely used by other GAEN apps.

254


255 Apps can measure duration far more accurately than distance, but the GAEN v1.1 duration cap  
256 of 30 minutes, combined with the use of 5 minute or similar windows, mean that only ~6-fold  
257 differences in the risk from low-attenuation exposures are captured in this way, or up to 8.6-fold  
258 when stochastic variation in attenuation over time also shows up at lower attenuations, or much  
259 longer in GAEN v1.5 where there is no cap on duration.

260

261 The relatively low predictive power of Bluetooth attenuation gives rise to diagonal patterns in the  
262 quarantine recommendations in Figure 3B. These diagonal patterns mean that quarantine will  
263 sometimes be recommended following prolonged exposure to a high shedder, even if the  
264 interaction took place at well beyond the estimated 2 m. distance. However, these exposures  
265 are not risk-free either, in particular if taking place in an indoor environment, especially in cases  
266 with heavy breathing, such as exercise environments<sup>20</sup> or choir rehearsals,<sup>21</sup> where aerosols  
267 may mix throughout the room and also deposit on surfaces. The diagonal pattern reflects the  
268 compelling evidence that exposure timing and duration also significantly contribute to infection  
269 risk. We therefore sometimes recommend quarantine recommendation even when Bluetooth  
270 attenuation, which is a poor proxy for distance, is not low. However, Bluetooth attenuation is  
271 nevertheless critical to concluding that an interaction occurred at all.

272





273  
 274 **Figure 3.** Examples of quarantine recommendations using a threshold for infection risk (B) vs.  
 275 for current or future infectiousness (C). Shaded cells indicate that a 30-minute interaction is  
 276 insufficient to trigger quarantine. A) Transmission risk levels 1-6 are used to capture the 10-fold  
 277 range of relative infectiousness on different days as a function of timing relative to symptom  
 278 onset. Evidence from both transmission pairs and TCID50 measurements is reviewed in the  
 279 Supplementary Materials Section 9. B) The minimum length interaction needed to trigger 14-day  
 280 quarantine is a function both of Bluetooth signal attenuation and of Transmission Risk Level.  
 281 Approaches that neglect the latter correspond to a single row of 15 minutes, and potentially a  
 282 second row of 30 minutes. C) Number of quarantine days recommended following a 30-minute  
 283 interaction.

284 So far, we have estimated the probability of infection from an exposure. Each day that passes  
285 without symptoms provides more information to make infection less likely, and eventually also to  
286 increase the probability that shedding from an asymptomatic infection has ended. To calculate  
287 the probability of current or future infectiousness on a subsequent day, conditional on no  
288 symptoms until that day, we apply a discount factor based both on time elapsed without  
289 symptoms and also any negative test results (Supplementary Materials Sections 5 and 6). We  
290 multiply the probability of infection from an exposure by this discount factor to determine the  
291 remaining risk of infectiousness from a given exposure.


292  
293 Traditional quarantine guidelines are binary (either 14 days from date of last exposure, or no  
294 quarantine required). However, a consistent approach to risk, combined with a desire to impose  
295 quarantine days in the most efficient manner possible to combat disease spread, suggests that  
296 individuals should quarantine for longer following a higher-risk exposure (Figure 4A) (although  
297 see Supplementary Materials Section 5 for a caveat with very high doses). This approach  
298 calculates the number of days post-interaction that would be needed to drop below a given  
299 threshold of probability of current or future infectiousness. Exposure scenarios of 30 minutes are  
300 illustrated in Figure 3C.

301  
302 We used a 0.13% threshold in Figure 3C, because it recommends a 14-day quarantine for 15  
303 minutes in close range with a high shedder. Such an interaction has a 1.12% infection risk,  
304 which falls below a 0.13% probability of current or future infectiousness after 14 days of  
305 quarantine during which no symptoms appear. Note that this initial infection risk is broadly  
306 compatible with the attack rate reported in Taiwan (1.0%, 95% CI: 0.6-1.6%) for those  
307 interacting with infected individuals in the first 5 days of symptom onset,<sup>22</sup> which is similar to the  
308 1.9% attack rate (95% CI 1.8%–2.0%) reported in South Korea.<sup>23</sup>

309  
310 Current advice treats the larger risk of longer exposure the same, making a 0.13% threshold  
311 more conservative because it is calculated to generate a 14-day quarantine for a minimal  
312 duration of exposure. However, this is offset by our assuming maximal shedding in calculating  
313 this benchmark example. In other words, while this threshold approximates the risk tolerance of  
314 current advice, the details of who is recommended for quarantine and for how long will be  
315 different in our quantification of total risk than it would be if we were to combine independent  
316 binary thresholds for infectious period of transmitters, duration of exposure, and distance to  
317 produce a quarantine duration of uniform length. This leads to more consistent treatment of risk  
318 to yield the greatest benefit in terms of transmission prevented per day of quarantine  
319 recommended. Shorter quarantines might significantly reduce the harms imposed by  
320 quarantine,<sup>24</sup> and increase compliance<sup>25</sup> (although see McVernon et al<sup>26</sup>). Quarantining for 14  
321 days post-exposure may be exceptionally challenging for essential workers, individuals without  
322 sick leave, or those who would endure significant financial hardship due to lost income.

323  
324 The assumed fraction of asymptomatic infections affects the discounting of risk. The  
325 symptomatic fraction is discounted according to the distribution of incubation periods from  
326 exposure to symptom onset, while releasing the asymptomatic fraction from quarantine is not  
327 safe until not only onset, but also shedding is over (Supplementary Materials Section 5). Our  
328 calculations so far assume that 20% of infections are asymptomatic. If we instead assume that  
329 50% infections are asymptomatic, e.g. in a young age group, even a 15-minute contact  
330 registered as low attenuation and with peak shedding in the transmitter would require a 16-day  
331 quarantine to meet a 0.13% threshold (Figure 4B). However, if an individual were to test

332 negative during their quarantine, their conditional probability of current or future infectiousness  
333 would drop, shortening their quarantine to 13 days for a test with 70% sensitivity (Figure 4C).  
334  
335



336  
337 **Figure 4.** Applying a consistent risk tolerance for current or future infectiousness causes  
338 quarantine duration to be a function of initial risk, of the tolerated degree of risk, of the fraction of  
339 infections that are assumed to be asymptomatic, and of any negative test results. A) Initial  
340 infection risk is 1.12% following 15 minutes of close contact with an individual around the time of  
341 symptom onset. With a 20% asymptomatic fraction, a 14-day quarantine is recommended under  
342 a 0.13% risk threshold, but only a 7-day quarantine under a 0.5% threshold. Following a lower  
343 risk exposure with 0.2% infection risk, quarantine would be 5 days with the stricter threshold,  
344 and there would be no quarantine with the less strict. B) Quarantine must be longer to mitigate a  
345 high likelihood of asymptomatic infection in the exposed individual. C) A negative test result,  
346 shown here as taking place on Day 5, can shorten quarantine, in particular mitigating the risk of  
347 asymptomatic infection. We apply Bayes theorem with 70% sensitivity and 100% specificity.  
348 Note that widespread availability of testing would allow much stricter risk thresholds to be used.  
349 Day 0 is included in the total quarantine times.  
350

## 351 Discussion

352  
353 Here we quantify relative risk of infection using experiments to inform the noisy distance-  
354 attenuation relationship, and Monte Carlo simulations to inform both this and other sources of  
355 variability and uncertainty that affect risk. We roughly calibrate relative infection risk to absolute  
356 probability of infection based on limited information from the infection probability of household  
357 contacts.  
358

359 Errors in calibration are likely but will generally not affect the rank order of risks. For example,  
360 adjusting the risk threshold of 0.13% for quarantine will have similar effects to adjusting the  
361 value of  $\lambda$ . Knowledge of absolute vs. relative risk does have some effect once some saturation  
362 in risk begins to occur, little of which will occur unless much longer durations are recorded.  
363

364 With 20% cases being asymptomatic and no testing, the risk of current or future infectiousness  
365 falls ~11-fold over the first 14 days of quarantine. Under GAEN v1.5, risk will sometimes differ  
366 more between two individuals entering quarantine than when comparing the same individual  
367 before vs. after a 14-day quarantine. For this reason, our scheme could recommend  
368 quarantines longer than 14 days. Variation in quarantine length is to be expected – if total risk is  
369 scored consistently, some quarantines will be longer and others shorter, in order for residual  
370 infection probability, conditional on time elapsed without symptoms, to fall below a threshold.  
371

372 The Covid Watch app is currently programmed either to use a threshold on infection risk to  
373 determine 14-day quarantine onset, or on risk of current and future infectiousness to determine  
374 both quarantine and duration. Either threshold can be set by public health authorities flexibly in  
375 the light of external factors such as level of community transmission, jurisdictional comfort with  
376 uncertainty related to digital exposure notifications, and current public health science and  
377 recommendations. Communities that have achieved containment might choose to set a stricter  
378 threshold, testing individuals once or twice to lower their risk following each negative test.

379  
380 Communities with high prevalence might raise the threshold if it seems likely that the number of  
381 quarantine recommendations being issued by the app will cause it to fall out of use. Note that  
382 the maximum possible initial infection risk in our v1.1 scheme is 3.23%; relaxing the 30-minute  
383 cap on durations, while maintaining infectiousness information, would be necessary in order to  
384 get resolution among higher risks. The effects of this problem are partly ameliorated by using  
385 the variable quarantine duration approach (Figure 3C). When a threshold is set well below the  
386 probability that a randomly chosen member of the population is currently infected, it should be  
387 recognized that individuals agreeing to download and comply with the recommendations of the  
388 app are implicitly agreeing to adhere to higher standards than those implied by the current  
389 absence of a general stay-at-home order. At the time of writing (September 5), the rate of  
390 current infection is ~1% in Arizona.<sup>27</sup>

391  
392 When the infection risk of the average person in the population is high, we believe that the best  
393 solutions are population-level restrictions and closures. Under these circumstances, a GAEN  
394 app might still have utility for essential workers. However, a GAEN app could be an inferior but  
395 still useful option should the political will for population-level restrictions not exist.

396  
397 As the conditional probability of current or future infectiousness (conditioned on the exposed  
398 individual being asymptomatic) falls throughout their quarantine period, messaging can also  
399 change. E.g., during the initial high risk days, users might be offered concrete resources such  
400 as grocery delivery, or the option to quarantine in a specialized facility in order to protect other  
401 household members, before transitioning to self-quarantine once risks falls. Even with self-  
402 quarantine, an app might identify the days on which staying home is the highest priority (i.e.  
403 days where the potential infectivity may be highest). Messaging considerations are discussed in  
404 Supplementary Material Section 10.

405  
406 We caution that our derived relationship between Bluetooth attenuation and infection risk is  
407 extremely approximate and model-dependent. We have more confidence in our settings of  
408 Transmission Risk Levels for symptomatic cases, but very little for asymptomatic cases. These  
409 parameters need to be calibrated with real world data on app users who report their app-  
410 recorded exposures to manual contact tracing efforts, who then track which users go on to test  
411 positive, and who are therefore able to mine the data to quantify the quantitative relationship  
412 between exposure details (duration, attenuation, Transmission Risk Level) and probability of  
413 infection. Transfer of this data to manual contact tracers' contact management databases is  
414 critical to improve the targeting of quarantine recommendations to those at highest risk of being  
415 infected, which will make most efficient use of each day of quarantine recommended to reduce  
416 transmission.

417

418 Short of this, more quantitative data on infectivity would be extremely valuable. Our  
419 determination of shedding duration partly relies on the prospective sampling of all individuals in  
420 a skilled nursing facility<sup>28</sup>, where many patients subsequently got sick. Daily samples during  
421 similar outbreaks could be used to quantify how shedding varies both among individuals and as  
422 a function of time relative to symptom onset. TCID50 data would be ideal, but even Ct values  
423 can be valuable for this purpose. However, the fact that the settings we originally chose based  
424 on infectivity data agreed with later and improved epidemiological approaches<sup>19,29</sup> is  
425 encouraging.

426  
427 Without extended durations, our default calibrations will not recommend quarantine (Figure 3B)  
428 or extended quarantine (Figure 3C) for lower Transmission Risks. However, with the duration  
429 cap lifted in a GAEN v1.5 or later, 43 minutes in the  $\leq 50$  dB range, 1.92 hours in the 50-70 dB  
430 range, or 7.93 hours in the  $>70$  dB range with an individual of transmission risk level 2 would be  
431 required. However, GAEN v1.5 does not quantify infectiousness, and GAEN v1.6 re-introduces  
432 only two levels of infectiousness. Limited durations and infectiousness information have been  
433 driven by privacy concerns, but this must be weighed against the significant ethical  
434 considerations in favor of efficient allocation of quarantine.<sup>30</sup> In Supplementary Section 10, we  
435 suggest an alternative method to preserve anonymity, which is to conceal all exposure details  
436 from the user's view. When using variable quarantine duration, this also effectively conceals the  
437 date of exposure.

438  
439 Our framework can be used not only to guide recommendations for who should quarantine and  
440 for how long, but also to allocate associated resources including quarantine facilities, grocery  
441 delivery and other social support, and priority for access to scarce tests. Both manual contact  
442 tracing and digital exposure notification require rapid testing to be effective. Given limited tests,  
443 targeting those at highest risk of infection will do the most good in finding new positive cases  
444 who are early enough in the course of infection for these approaches to stem transmission the  
445 most.

446  
447 **Data Availability:** Supplementary Data Table 1 provides the alpha test data used to calibrate  
448 our weights.

449  
450 **Code Availability:** Code and necessary data are accessible under a Creative Commons  
451 license at [https://github.com/awilson12/risk\\_scoring](https://github.com/awilson12/risk_scoring)

## 452 453 **Acknowledgements**

454  
455 We thank the many testers who participated in alpha testing of the app for their time and  
456 feedback, including those attempting to test in Androids who were stymied by technical issues.  
457 We also thank Marm Kilpatrick for literature pointers, Jacob Steinhardt and Bruce Helming for  
458 comments on a draft manuscript, Dave Lines for writing instructions for executing test scenarios  
459 and providing participant support, Ami Buczek for installing the app on loaner phones, Danielle  
460 Zhou for helping with testing instructions, setting up test logs, and making test assignments, all  
461 of the Covid Watch team for agreeing to include our risk scoring scheme into their app, Yuanxia  
462 Li and Sudha Ram for agreeing to let us publish alpha testing data ahead of and separately  
463 from their analysis, Luca Ferretti for sharing a manuscript in preparation that helped confirm our

464 choice of pre-symptomatic Transmission Risk Scores, Gary Windham for doing the code  
465 reviews that led the University of Arizona to adopt Covid Watch, Darcy Van Patten for  
466 organizing the details of that adoption, and Joyce Schroeder for her leadership of the Covid  
467 Watch pilot at the University of Arizona. Funding was provided by the University of Arizona.  
468

## 469 **Competing Interests**

470  
471 JIP, ZS, MX, SH, TW, and JM are members of Covid Watch, a 501 (c)(3) non-profit developing  
472 open source code software for exposure notifications. The organization is also involved in  
473 providing commercial solutions around the technology.  
474

## 475 **Author Contributions**

476  
477 JM conceived the overall risk scoring approach and oversaw all aspects of the project. AMW,  
478 PIB, and JM designed the Gaussian plume component, and AMW implemented it. JM and AMW  
479 reviewed the literature to choose Transmission Risk Levels. JM designed and implemented the  
480 variable quarantine approach. MX and JMc designed and managed the alpha testing. JIP  
481 preprocessed and cleaned the alpha test data. YC and YJS designed and performed people  
482 traffic simulations to inform a realistic distribution of distances. NA implemented the rebalancing  
483 procedure to reflect that distribution, and performed sampling to choose weights. AMW and JM  
484 calibrated the dose-response curve and NA explored its sensitivity to variance in dose. JIP, ZS,  
485 SH, and TW designed and implemented the core components of the Covid Watch app used in  
486 the alpha testing. JIP modified the app to obtain high resolution attenuation data. ZS provided  
487 up-to-date guidance about what is possible under GAEN, and checked calculations. PIB and  
488 KCE provided input on all public health aspects of the research. AMW and JM wrote the first  
489 draft of the manuscript, followed by significant input from PIB and KCE.  
490

## 491 **References**

- 492  
493 1 Armbruster B, Brandeau ML. Contact tracing to control infectious disease: When enough  
494 is enough. *Health Care Manag Sci* 2007; **10**: 341–55.  
495 2 Kucharski AJ, Klepac P, Conlan A, *et al*. Effectiveness of isolation, testing, contact tracing  
496 and physical distancing on reducing transmission of SARS-CoV-2 in different settings.  
497 *medRxiv* 2020; **3099**: 2020.04.23.20077024.  
498 3 Aleta A, Martin-Corral D, Pastore Y Piontti A, *et al*. Modeling the impact of social  
499 distancing, testing, contact tracing and household quarantine on second-wave scenarios  
500 of the COVID-19 epidemic. *medRxiv Prepr Serv Heal Sci* 2020; : 1–31.  
501 4 Bi Q, Wu Y, Mei S, *et al*. Epidemiology and transmission of COVID-19 in 391 cases and  
502 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet*  
503 *Infect Dis* 2020; **3099**: 1–9.  
504 5 Ferretti L, Wymant C, Kendall M, *et al*. Quantifying SARS-CoV-2 transmission suggests  
505 epidemic control with digital contact tracing. *Science (80- )* 2020; **368**: eabb6936.  
506 6 Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM,  
507 Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-  
508 19: a modelling study. *Lancet Public Heal* 2020; **5**: e452–9.  
509 7 Fraser C, Abeler-Dörner L, Ferretti L, Parker M, Kendall M, Bonsall D. Digital contact  
510 tracing: comparing the capabilities of centralised and decentralised data architectures to  
511 effectively suppress the COVID-19 epidemic whilst maximising freedom of movement and

- 512 maintaining privacy. Introduction 2. 2020.
- 513 8 Von Arx S, Becker-Mayer I, Blank D, *et al.* Slowing the Spread of Infectious Diseases  
514 Using Crowdsourced Data. Covid Watch. 2020. [https://blog.covidwatch.org/en/covid-](https://blog.covidwatch.org/en/covid-watch-whitepaper-using-crowdsourced-data-to-slow-virus-spread)  
515 [watch-whitepaper-using-crowdsourced-data-to-slow-virus-spread](https://blog.covidwatch.org/en/covid-watch-whitepaper-using-crowdsourced-data-to-slow-virus-spread) (accessed Aug 19,  
516 2020).
- 517 9 Salathé M, Althaus CL, Anderegg N, *et al.* Early Evidence of Effectiveness of Digital  
518 Contact Tracing for SARS-CoV-2 in Switzerland. Github. 2020; : 1–18.
- 519 10 Webster RK, Brooks SK, Smith LE, Woodland L, Wessely S, Rubin GJ. How to improve  
520 adherence with quarantine: rapid review of the evidence. *Public Health* 2020; **182**: 163–9.
- 521 11 Haas CN, Rose JB, Gerba CP. Quantitative Microbial Risk Assessment. John Wiley and  
522 Sons, 1999.
- 523 12 Farrell S, Leith DJ. Pairwise Handset Types and Orientations Are Sufficient to Blur  
524 Exposure Notification Thresholds. Trinity Coll. Dublin, Irel. 2020.  
525 <https://down.dsg.cs.tcd.ie/tact/posorient.pdf> (accessed Aug 6, 2020).
- 526 13 Zhang N, Su B, Chan PT, Miao T, Wang P, Li Y. Infection spread and high-resolution  
527 detection of close contact behaviors. *Int J Environ Res Public Health* 2020; **17**.  
528 DOI:10.3390/ijerph17041445.
- 529 14 Curmei M, Ilyas A, Evans O, Steinhardt J. Estimating Household Transmission of SARS-  
530 CoV-2. *medRxiv* 2020. DOI:10.1101/2020.05.23.20111559.
- 531 15 World Health Organization. Considerations for quarantine of individuals in the context of  
532 containment for coronavirus disease (COVID-19). 2020.  
533 [https://www.who.int/publications/i/item/considerations-for-quarantine-of-individuals-in-the-](https://www.who.int/publications/i/item/considerations-for-quarantine-of-individuals-in-the-context-of-containment-for-coronavirus-disease-(covid-19))  
534 [context-of-containment-for-coronavirus-disease-\(covid-19\)](https://www.who.int/publications/i/item/considerations-for-quarantine-of-individuals-in-the-context-of-containment-for-coronavirus-disease-(covid-19)) (accessed July 1, 2020).
- 535 16 European Centre for Disease Prevention and Control. Public health management of  
536 persons, including healthcare workers, having had contact with COVID-19 cases in the  
537 European Union - second update. ECDC. 2020. DOI:10.2807/1560-  
538 7917.ES.2020.25.9.2000202.
- 539 17 Centers for Disease Control and Prevention. Coronavirus Disease 2019 Community-  
540 Related Exposures. 2020. [https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html)  
541 [recommendations.html](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html) (accessed Jan 7, 2020).
- 542 18 Bullard J, Dust K, Funk D, *et al.* Predicting infectious SARS-CoV-2 from diagnostic  
543 samples. *Clin Infect Dis* 2020; : 1–18.
- 544 19 Ashcroft P, Huisman JS, Lehtinen S, *et al.* COVID-19 infectivity profile correction. *arXiv*  
545 2020. <http://arxiv.org/abs/2007.06602>.
- 546 20 Jang S, Han SH, Rhee J-Y. Cluster of Coronavirus Disease Associated with Fitness  
547 Dance Classes, South Korea. *Emerg Infect Dis* 2020; **26**. DOI:10.3201/eid2608.200633.
- 548 21 Hamner L, Dubbel P, Capron I, *et al.* High SARS-CoV-2 Attack Rate Following Exposure  
549 at a Choir Practice - Skagit County, Washington, March 2020. *Morb Mortal Wkly Rep*  
550 *High* 2020; **69**: 606–10.
- 551 22 Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact Tracing Assessment of  
552 COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods  
553 before and after Symptom Onset. *JAMA Intern Med* 2020.  
554 DOI:10.1001/jamainternmed.2020.2020.
- 555 23 Park YJ, Choe YJ, Park O, *et al.* Contact Tracing during Coronavirus Disease Outbreak,  
556 South Korea, 2020. *Emerg Infect Dis J* 2020; **26**. DOI:10.3201/eid2610.201315.
- 557 24 Brooks SK, Webster RK, Smith LE, *et al.* The psychological impact of quarantine and  
558 how to reduce it: rapid review of the evidence. *Lancet* 2020; **395**: 912–20.
- 559 25 Soud FA, Cortese MM, Curns AT, *et al.* Isolation compliance among university students  
560 during a mumps outbreak, Kansas 2006. *Epidemiol Infect* 2009; **137**: 30–7.
- 561 26 McVernon J, Mason K, Petrony S, *et al.* Recommendations for and compliance with

562 social restrictions during implementation of school closures in the early phase of the  
563 influenza A (H1N1) 2009 outbreak in Melbourne, Australia. *BMC Infect Dis* 2011; **11**.  
564 DOI:10.1186/1471-2334-11-257.  
565 27 covid19-projections.com. 2020. <https://covid19-projections.com/us-az> (accessed Sept 5,  
566 2020).  
567 28 Arons MM, Hatfield KM, Reddy SC, *et al*. Presymptomatic SARS-CoV-2 infections and  
568 transmission in a skilled nursing facility. *N Engl J Med* 2020; **382**: 2081–90.  
569 29 Ferretti L, Ledda A, Wymant C, *et al*. The timing of COVID-19 transmission. *medRxiv*  
570 2020. DOI:10.1101/2020.09.04.20188516.  
571 30 Singer P, Masel J. How (Not) to Fight COVID 19. Proj. Synd. 2020; published online Sept  
572 3. [https://www.project-syndicate.org/commentary/tech-solutions-to-targeting-covid19-](https://www.project-syndicate.org/commentary/tech-solutions-to-targeting-covid19-quarantine-by-peter-singer-and-joanna-masel-2020-08)  
573 [quarantine-by-peter-singer-and-joanna-masel-2020-08](https://www.project-syndicate.org/commentary/tech-solutions-to-targeting-covid19-quarantine-by-peter-singer-and-joanna-masel-2020-08).  
574



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## Supplemental Materials for

### Quantifying SARS-CoV-2 infection risk within the Google/Apple exposure notification framework to inform quarantine recommendations

Amanda M. Wilson<sup>1</sup>, Nathan Aviles<sup>2</sup>, James I. Petrie<sup>3</sup>, Paloma I. Beamer<sup>1</sup>, Zsombor Szabo<sup>3</sup>, Michelle Xie<sup>3</sup>, Janet McIllece<sup>4</sup>, Yijie Chen<sup>5</sup>, Young-Jun Son<sup>5</sup>, Sameer Halai<sup>3</sup>, Tina White<sup>3</sup>, Kacey C. Ernst<sup>1</sup>, Joanna Masel<sup>6,\*</sup>

<sup>1</sup> Mel & Enid Zuckerman College of Public Health, University of Arizona

<sup>2</sup> Graduate Interdisciplinary Program in Statistics, University of Arizona

<sup>3</sup> Covid Watch

<sup>4</sup> World Wide Technology

<sup>5</sup> Systems and Industrial Engineering, University of Arizona

<sup>6</sup> Ecology & Evolutionary Biology, University of Arizona

\* corresponding author [masel@email.arizona.edu](mailto:masel@email.arizona.edu)

ORCID: AMW 0000-0003-3259-8169, NA 0000-0001-9998-4406, JIP 0000-0001-7959-7687, PIB 0000-0001-5287-2183, ZS 0000-0002-3653-1378, MX 0000-0001-9512-3684, YC 0000-0001-5316-4103, YS 0000-0002-4004-2155, KCE 000-0002-3346-7788 JM 0000-0002-7398-2127

24	<b>Contents</b>	
25	Supplementary Table 1. Parameter values used by app to calculate risk .....	3
26	Supplementary Table 2. Parameter values used by us to calibrate parameter values in Table 1....	4
27	1.0 Experiments on Distance-Attenuation Relationship.....	4
28	Figure S1.....	5
29	2.0 Estimation of Exposure Concentrations.....	6
30	3.0 Inhalation Dose per Interaction.....	7
31	4.0 Setting attenuation bin thresholds and corresponding weights.....	7
32	5.0 Probability of Current or Future Infectiousness.....	8
33	6.0 Negative Test Results and Recommending a Day for Testing .....	8
34	7.0 Multiple Exposures and Total Risk.....	9
35	8.0 Variance in Dose.....	9
36	Figure S2.....	10
37	9.0 Transmission Risk Levels .....	10
38	10.0 Considerations in recommending and messaging variable quarantine durations .....	11
39	References.....	13
40		
41		
42		

43 **Supplementary Table 1. Parameter values used by app to calculate risk**

Parameter	Description	Distribution or Point Value		References
$S$	Viral shedding rate in arbitrary units that are proportional to viral copies/m <sup>3</sup>	10 <sup>1</sup>	5 days pre- or 8-9 days post-symptom onset	10-fold range informed by TCID50 measures <sup>1</sup> , timing informed by <sup>1-4</sup>
		10 <sup>1.2</sup>	6-7 days post-symptom onset, or asymptomatic within 2-4 days of test	
		10 <sup>1.4</sup>	4 days pre- or 5 days post-symptom onset, or asymptomatic within 1 day of test	
		10 <sup>1.6</sup>	3 days pre- or 4 days post-symptom onset	
		10 <sup>1.8</sup>	2 days pre- or 3 days post-symptom onset	
		10 <sup>2</sup>	1 day pre- to 2 days post-symptom onset	
$T_{low}, T_{med}, T_{high}$	Duration of exposure	Durations for Bluetooth attenuations ≤50dB, between 50dB and 70dB, and >70dB are multiplied by weights 2.15, 0.79, 0.19, respectively		This study
$\lambda$	Probability that one viral particle establishes infection × conversion from arbitrary units	3.50 x 10 <sup>-6</sup>		Calibrated from secondary attack rate of household contacts = 30%. <sup>5</sup>
Fraction of asymptomatic infections	Higher values lead to longer quarantine	20% for a population, but depends on age		<sup>6</sup>
Incubation period	Days until symptom onset	Probabilities for {0,1,2,...} days = {0,4E-05, 0.011842, 0.088541, 0.181965, 0.207344, 0.174797, 0.123761, 0.081488, 0.051057, 0.031469, 0.018734, 0.011235, 0.006786, 0.00422, 0.002518, 0.001626, 0.000978, 0.000592, 0.000364, 0.000231, 0.00014, 0.000093, 0.000062, 0.00004, 0.000025, 0.000017, 0.000011, 0.000008}		<sup>7</sup>
Asymptomatic shedding duration	We assume that asymptomatic shedding begins 3 days before what would have been the day of symptom onset if symptomatic, or else immediately upon infection, whichever occurs later, and that shed viral particles are nonviable beyond 12 days	Cumulative probabilities for days {5,6,7,...} = {0.054054054, 0.094594595, 0.12162162, 0.148648649, 0.189189189, 0.21621621, 0.256756757, 1}		<sup>8,9</sup>
Risk threshold	Set by public health agency, cognizant of limitations in current calibration of $\lambda$	Benchmark of 0.5% for probability of infection or 0.13% for probability of current or future infectiousness		This study

44

45 **Supplementary Table 2.** Parameter values used by us to calibrate parameter values in Table 1

Parameter	Description	Distribution or Point Value	References
$X$	Exhalation rate (m <sup>3</sup> /day)	Normal(16.3, 4.15), left-truncated at 9	<sup>10</sup>
$A$	Cross-sectional area of the mouth. Used to calculate the breath velocity, $U$ from $X$	Uniform(23, 59) (cm <sup>2</sup> )	<sup>11</sup>
$I_y$	“Lateral intensity” of plume deviation	Uniform(0.08, 0.25)	<sup>12</sup>
$I_z$	“Vertical intensity” of plume deviation	Uniform(0.03, 0.07)	
$I$	Inhalation rate (m <sup>3</sup> /day)	Normal(16.3, 4.15), left-truncated at 9	<sup>10</sup>
$\rho$	Distance	Sampled from attenuation-distance dataset to inform weights.	This study
$\varphi$	Angle between the z-axis and the xy-plane	Used while informing weights. If $\rho \leq 1$ m, $\varphi = \pi/2$ , If $\rho > 1$ m, $\varphi$ randomly sampled from Triangular(min= $\pi/4$ , mode= $\pi/2$ , max= $3\pi/4$ )	1 m. cutoff for face-to-face interaction informed by <sup>13</sup>
$\theta$	Angle between x and y axes	Used while informing weights. If $\rho \leq 1$ m, $\theta = 0$ , If $\rho > 1$ m, $\theta$ randomly sampled from Uniform(0, $2\pi$ )	1 m. cutoff for face-to-face interaction informed by <sup>13</sup>


46  
47

48 **1.0 Experiments on Distance-Attenuation Relationship**

49 Using a developer version of the Covid Watch app, we called the API multiple times with different attenuation  
50 thresholds in order to achieve resolution of 3dB in the 30dB-99dB range. The API appears to round up durations to  
51 5-minute increments, each with its own attenuation value; we consider each of these to be a datapoint. Our tests  
52 were all short, e.g. a 12-minute test would yield 3 datapoints.

53 There were 7 testers and 14 phones, representing a variety of models, all of iPhones – handset type and orientation  
54 can affect signal.<sup>14</sup> 49 measurements were taken with specific phone orientations, while for the remaining 986 the  
55 devices were side-by-side and facing upwards if not otherwise specified by the barrier type (e.g. pocket). 203, 222,  
56 199, 374, 17, 20 measurements were at 0.5m., 1m., 1.5m., 2m., 3m., and 5m., respectively. We also used the 28, 28,  
57 29, 27, and 16 zero-risk barrier measurements at 0.5m., 1m., 1.5m., 2m., and “N/A”, respectively. Note that  
58 improvements made in GAEN v1.5 are expected to improve our ability to estimate distance as a function of  
59 attenuation. While useful, we note that new experimental data would be required for recalibration. The imbalanced  
60 nature of the collected data, with few long distance measurements and no Android measurements, reflects the fact  
61 that the decision was made to recommence once v1.5 was available, whose calibration will be both qualitatively and  
62 quantitatively different.

63  
64 1163 out of the total 1558 datapoints were used for attenuation weight and attenuation threshold setting, with  
65 exclusions of data described in Figure S1. The 1163 non-excluded datapoints are supplied in Supplementary Dataset  
66 1. Of the included 1035 attenuation measures that involved infection risk, 747 did not include a deliberate barrier,  
67 while 288 includes barriers such as pockets, backpacks, nearby laptop, and human body. 925 measures were taken  
68 inside homes, 49 were taken inside an elevator, and 61 outside.  
69



70

71 **Figure S1. Attenuation data cleaning**

72 \*A few attenuation values were implausibly low, always representing one such increment per device per series of  
73 attenuation values corresponding to a single test. We believe this is because these testers used the dropdown menu to  
74 turn off Bluetooth rather than going to Settings, and this only disables existing Bluetooth connections, causing an  
75 anomalously strong signal to be recorded during the period in which the test was being set up. We manually  
76 annotated these, totaling 144 datapoints, and excluded them from further analysis, yielding 1414 datapoints.

77 \*\*Distance is not needed for the 128 datapoints taken in the presence of a risk-blocking barrier (e.g. closed car doors  
78 or walls), so points marking "N/A" for distance were not excluded for any of these.

79

80

81

82 To rebalance the distance measurements, we created a pseudo-dataset with different multiples of the data collected  
83 at each of the distances. To inform the desired distribution of distances, we analyzed the time-weighted pairwise  
84 distance in traffic flow simulations of a classroom.<sup>15</sup> These indicate a roughly uniform distribution over possible  
85 distances, with a reduction in close contact due to attempts to adhere to social distancing rules. Since close contact  
86 might be more common in other settings, and distances beyond 5m. can also register Bluetooth signal, we made 5, 5,  
87 6, 3, 132, and 168 copies of the non-zero-risk data at distances of 0.5m., 1m., 1.5m., 2m., 3m., and 5m, respectively,  
88 yielding a data ratio of 1015 : 1100 : 1194 : 1122 : 2244 : 3360 (as a rough approximation of a target ratio of  
89 1:1:1:2:3) prior to the sampling described below. To this, we added 4 copies of the zero-risk barrier measurements,  
90 so that they made up 4.85% of the total pseudo-dataset.

91

92 Our calibration code holds shedding rate and exposure duration constant at 50 arbitrary units/m<sup>3</sup> and 30 minutes, in  
93 order to isolate the effect of distance on differences in dose between attenuation buckets.

## 94 2.0 Estimation of Exposure Concentrations

95  
96 It is well-acknowledged that both distance from an infected individual and duration of “close proximity  
97 interactions”<sup>16</sup> are important parameters in estimating the probability of infection of those exposed.<sup>17-20</sup> However,  
98 there is little quantitative information about the relationship between distance and risk of infection. Chu et al.  
99 (2020)<sup>18</sup> quantified risk in terms of answers to binary survey questions about whether the respondent came within  
100 distance  $X$  of an infected person. They found that the value of the threshold distance  $X$  in the survey question  
101 predicts the degree to which the answer predicts risk, but this relationship cannot easily be converted into one  
102 between actual distance and risk.

103  
104 For this reason, we instead model the dose inhaled at different distances. Exhaled breath is a likely source of  
105 infection.<sup>21,22</sup> Accordingly, we model a Gaussian plume<sup>23</sup> of virus-containing aerosols originating from the emitter’s  
106 face at (0,0,0). The  $x$  axis represents the direction that the transmitter is facing and breathing toward with breath  
107 velocity  $U$  (m/s). Diffusion causes spread away from  $y=0$  or  $z=0$ . The viral concentration is then  
108

$$109 \quad C(x, y, z) = \frac{Q}{U} \frac{1}{2\pi\sigma_y\sigma_z} e^{\frac{-y^2}{2\sigma_y^2}} e^{\frac{-z^2}{2\sigma_z^2}} \quad (1)$$

$$110 \quad Q = SX \quad (1.1)$$

$$111 \quad U = X/A \quad (1.2)$$

112  
113 where  $Q$  is virus emitted per second and is equal to the product of shedding rate,  $S$ , (in arbitrary units proportional to  
114 copies/m<sup>3</sup>) and an exhalation rate,  $X$ , (taken from measured inhalation rates in m<sup>3</sup>/s), yielding arbitrary units  
115 proportional to copies per second being generated (eq 1.1). We sample our exhalation rates from a normal  
116 distribution of inhalation rates with a mean and standard deviation of 16.3 and 4.15 m<sup>3</sup>/day, respectively. These were  
117 informed by the 16-21 year old range from Table 6-1 in the Exposure Factors Handbook (2011).<sup>10</sup> To avoid negative  
118 exhalation rates, this distribution was left-truncated at 9 m<sup>3</sup>/day, the smallest fifth percentile of inhalation rates for  
119 males and females in age ranges overlapping with the 16-21 year old range.<sup>10</sup> The velocity of breath  $U$  (m/s) was  
120 determined by dividing the exhalation rate (m<sup>3</sup>/s) by the cross-sectional area of an open mouth  $A$  (m<sup>2</sup>), which is the  
121 area over which air is assumed to be exhaled at the plume source. The cross-sectional area was informed by a  
122 uniform distribution with minimum and maximum cross-sectional areas measured for an open mouth with a “large  
123 bite” configuration, ranging from 23 to 59 cm<sup>2</sup>.<sup>11</sup> Note that for a steady-state plume assuming a continuous output of  
124 virus, the effects of the exhalation rate (volume of air per second) on amount of virus emitted, and on the velocity  
125 with which they disperse, cancel out. For an abrupt exhalation such as a cough, rather than steady state, a higher  
126 exhalation rate would affect viral airborne concentration.  
127  
128

129  
130 For interactions  $\leq 1$ m, we assumed two people interacting are directly in front of each other along the  $x$ -axis ( $\phi = \pi$   
131 /2,  $\theta=0$ ). For interactions beyond the close range ( $>1$ m), we sample  $\theta$  from a uniform 360 degrees ( $\min=0$ ,  $\max=2\pi$ ),  
132 and the angle between the  $z$  axis and the  $xy$ -plane,  $\phi$ , was randomly sampled from a triangular distribution ( $\min=\pi/4$ ,  
133  $\text{mode}=\pi/2$ ,  $\max=3\pi/4$ ). We then convert from spherical units to (x,y,z) to apply Eq. 1. We assumed that scenarios  
134 where the person exposed was behind the emitter ( $x<0$ ) resulted in a zero dose.

135  
136 To capture the shape of the plume, we use:

$$137 \quad \sigma_y = I_y x \quad (2)$$

$$138 \quad \sigma_z = I_z x \quad (3)$$

139  
140 Assuming moderately stable conditions,  $I_y$  and  $I_z$  were randomly sampled from uniform distributions with  
141 minimums and maximums of 0.08-0.25 and 0.03-0.07, respectively.<sup>12</sup>  
142  
143  
144

145 We note that inhalation and exhalation rates are both likely important to risk. For example, one infected dance  
146 instructor spread COVID-19 to 7/26 other instructors at a four hour workshop,<sup>24</sup> representing a similar risk as for  
147 household contacts, despite the presumption that most were at >2 m. distance for most of this time. Limited air  
148 circulation or increased respiratory rates are important factors that cannot be captured in the current GAEN  
149 approach, but the four-hour duration of the workshop could be, combined with considerable uncertainty in the  
150 relationship between Bluetooth attenuation and distance, in order to correctly capture the high risk of such a  
151 scenario.

152  
153 While wind velocity and relative humidity are important factors for determining droplet and fine aerosol dispersion  
154 and deposition,<sup>25,26</sup> as is mask usage, these are uncertain factors that are not recorded by the app, especially  
155 considering that interactions may occur indoors or outdoors. By not accounting for deposition, and by assuming that  
156 masks are either not worn or not worn effectively, we will tend to overestimate dose at greater distances, and in the  
157 presence of masks. This will implicitly lower the app-imposed risk tolerance of individuals who comply with public  
158 health guidelines that recommend masks and physical distancing, and who might therefore also be more inclined to  
159 comply with quarantine recommendations. The 2-meter rule was based on the assumption that most transmission is  
160 via droplets (large aerosols) for which deposition occurs over this distance. However, there is increasing evidence  
161 for transmission via smaller aerosols,<sup>27-31</sup> supporting our assignment of some risk to greater distances, reflecting  
162 short- to medium-distance airborne transmission.

### 164 3.0 Inhalation Dose per Interaction

165  
166 An inhaled dose of viral particles due to person-to-person interactions was estimated based on the duration of the  
167 interaction (minutes) ( $T$ ), the concentration of virus in the air at this  $\{x,y,z\}$  coordinate during the interaction  
168 (arbitrary units of viral particles/m<sup>3</sup>)  $C(x, y, z)$ , and inhalation rates (m<sup>3</sup>/minute) ( $I$ ),

$$170 \quad D = T \cdot I \cdot C(x, y, z) \quad (4)$$

171  
172 Inhalation rates were randomly sampled from the same distribution as exhalation rates but allowing for a different  
173 value per iteration. As with exhalation rates, we left-truncated the distribution to avoid negative inhalation rates and  
174 therefore negative doses. Figure 2 shows the expected dose as a function of distance, with a discontinuity at 1m.  
175 arising from our assumption that this distance or below indicates face-to-face interaction.

### 176 4.0 Setting attenuation bin thresholds and corresponding weights

177  
178 To select the threshold values (a, b) demarcating 3 attenuation bins, we optimized the differences in mean dose  
179 between two randomly sampled attenuation measurements. Specifically, we maximized the value of

$$181 \quad d(a, b) = \sqrt{2p_A p_B (A - B)^2 + 2p_B p_C (B - C)^2 + 2p_A p_C (C - A)^2}$$

182  
183 where  $A, B$  and  $C$  are the average doses  $D$  from Eq. 4, averaged across Monte Carlo sampling described above,  
184 corresponding to bins  $[0, a]$ ,  $(a, b]$ , and  $(b, +)$ , and  $p_A, p_B$ , and  $p_C$  are the probabilities that an attenuation will fall  
185 within that bin in our pseudo dataset.

186  
187 We examined multiple local maxima of this distance measure before choosing a partition pair. We also investigated  
188 alternative versions of a distance metric and alternative rebalancing schemes, to confirm that this is a relatively  
189 robust partition pair.

## 190 **5.0 Probability of Current or Future Infectiousness**

191  
192 To calculate residual risk of infection as a function of initial risk plus time since exposure, we use the probability  
193 distribution of incubation periods from Lauer et al.<sup>7</sup>, available at  
194 <https://iddynamics.jhsph.edu/apps/shiny/activemonitr/>. Note that it is possible that incubation periods are even more  
195 dispersed than reported here<sup>32</sup>; this would lengthen quarantine recommendations.

196  
197 To calculate risk of current or future infectiousness, we assume a fraction of symptomatic vs. asymptomatic cases  
198 and take an average of the discount factors applying in each case. Across a population, 20% of infections are  
199 estimated to be asymptomatic.<sup>34</sup> Younger users are more likely to be asymptomatic<sup>33</sup>, so the fraction of  
200 asymptomatic cases could be personalized on the basis of user age if that information is collected on a voluntary  
201 basis. For the symptomatic cases, we discount according to the probability of subsequently developing symptoms,  
202 given that symptoms have not appeared yet.

203  
204 For the asymptomatic cases, we combine the incubation periods from Lauer et al.<sup>7</sup> with a distribution of shedding  
205 durations. Long et al.<sup>8</sup> report slightly longer shedding durations for asymptomatic than symptomatic shedding, but  
206 other studies<sup>34-38</sup> for which we were unable to obtain the data, report the opposite, or no difference. Shedding  
207 declines in magnitude post symptom onset and is considered by the CDC to have reached negligible levels by 10  
208 days post symptom onset. We assume that asymptomatic shedding begins 3 days before what would have been the  
209 day of symptom onset if symptomatic, or else immediately upon infection, whichever occurs later.

210  
211 Using this assumption, we calculated the probability distribution of the day that shedding ends, given both the  
212 distribution of incubation periods and a distribution of shedding durations. For the latter, we combine the  
213 asymptomatic and symptomatic shedding durations of Long et al. but on the basis of CDC advice for isolation, we  
214 truncate the distribution so that all shedding periods longer than 12 days are recorded as exactly 12 days.

215  
216 Note that low dose exposures, e.g. to asymptomatic individuals, may result in longer incubation periods,<sup>32</sup>  
217 suggesting that low initial risk scores should have longer rather than the shorter quarantines we calculate using this  
218 method. We currently ignore this by assuming that risk scores primarily capture uncertainty in the likelihood of  
219 infection with a minimal dose, and not variation in the infecting dose once above the minimal. To see how this  
220 assumption arises from our model, note that the exponential dose-response curve we use assumes that each virus has  
221 an independent probability of initiating infection. Under the resulting Poisson distribution for the number of viruses  
222 responsible for the initial infection, then even for the 30% infection rate of household contacts, the probability that  
223 infection is initiated with two or more viruses is only 5%, and with three or more viruses is only 0.6%. However, the  
224 higher variance in dose explored in Figure S2 could make initiation with multiple viruses common enough to matter  
225 for high infection probabilities. In this case, our simplifying assumption might require overly long quarantines  
226 following very high risk exposures. However, unless the variance is extreme, it might not significantly distort  
227 estimated probabilities among the range of lower risk exposures. We note that lognormal distributions of incubation  
228 periods with substantial variance occur even in the absence of variation in dose, due both to variance in within-host  
229 replication rate and to the stochastics of establishing infection in the first cells.<sup>39</sup>

## 230 **6.0 Negative Test Results and Recommending a Day for Testing**

231  
232 Incorporation of negative test results can help exclude asymptomatic infection and hence allow for earlier release.  
233 From Bayes Theorem, and taking the false positive rate as negligible, a negative test result changes the probability  
234 of infection from  $p$  to  $\frac{Ep}{(1-(1-E)p)}$ , where  $E$  is the false negative rate. This could be taken as 0.3<sup>40,41</sup> or made  
235 dependent on the timing of the test relative to exposure,<sup>42</sup> which would require distinct application to each of  
236 multiple exposures.

237



238 Kucirka et al.<sup>42</sup> report a false negative rate as a function of the timing of a PCR test relative to symptom onset, but  
239 most of the data is post-symptom onset, with only a single patient's data informing false positive rates prior to  
240 symptom onset. If sufficient data on false negative rates pre-symptom onset became available on a larger number of  
241 patients, it could be combined with the distribution of incubation periods to calculate the false negative rate as a  
242 function of time since exposure. Before use as  $E$  in Bayes Theorem above, it can be adjusted in a form of  
243 survivorship analysis; if testing is conditional on no symptoms to date, then the ratio of pre-symptomatic :  
244 asymptomatic individuals in the reference group will depend on time since exposure. Time-dependent false negative  
245 rates could then be used to recommend an optimal day for testing. For example, we could choose the days on which  
246 the probability of obtaining positive test results is highest.

247  
248 We calculated this probability as the sensitivity on that day  $\times$  the conditional probability of infection on that day  
249 given no symptoms to date. Given exposures on multiple days, the sum of this product can be computed to choose a  
250 date for testing. Alternative criteria for optimization could also be devised, e.g. explicitly prioritizing highly exposed  
251 individuals whose calculated quarantine in the absence of a test would exceed 14 days, or assigning a value to  
252 testing immediately after quarantine begins, in the service of rapid tracing of that individual's contacts should they  
253 test positive.

## 254 7.0 Multiple Exposures and Total Risk

255  
256 GAEN v1.1 will not record either a single long exposure or multiple exposures from a single individual beyond the  
257 30 minutes cap for each of three attenuation bins, although this has changed in v1.5. However, it will record  
258 exposures happening on different days (considered to change at midnight UTC) as independent exposures. To  
259 calculate total risk, we combine the probabilities  $p_i$  of each exposure  $i$ , each discounted as described in the section  
260 above, as  $1 - \prod_i(1 - p_i)$ .

261  
262 Figures 3 and 4 illustrate scenarios of a single exposure. When there are multiple exposures, quarantine durations are  
263 determined with respect to total risk. The risk threshold for initiation and completion of quarantine are the same. In  
264 other words, risk is treated in an internally consistent fashion to achieve the maximum possible benefit from a given  
265 number of recommended quarantine days across a population. When fixed quarantine durations are used, exposure  
266 must be significant on a single day, from which the 14 days are then calculated, and risks are not integrated across  
267 multiple days.

## 268 8.0 Variance in Dose


269  
270 Our dose response curve is actually the probability of infection as a function of the expectation of dose, rather than  
271 dose. To consider the effect of variance in dose, we note that while  $E[1 - e^{-\lambda D}]$  is analytically intractable with  
272 respect to a lognormally distributed dose, there is a viable saddle point approximation described by Rojas-  
273 Nandayapa (2008) While Eq. 5.6 in Rojas-Nandayapa contains a typo, we use the method given to derive  
274

$$275 \quad 1 - E[e^{-\lambda D}] = 1 - \left[ \frac{1}{\sqrt{1 + LW(\theta \sigma^2 e^{\mu})}} \exp\left(\frac{LW^2(\theta \sigma^2 e^{\mu}) + 2LW(\theta \sigma^2 e^{\mu})}{2\sigma^2}\right) \right], \quad (6)$$

276  
277 where  $LW(x)$  is the Lambert-W function.

278  
279 Using this approximation, or the associated importance sampling method (Asmussen et al., 2016) which yields  
280 similar results, we can compare the shape for the dose response curves and consider whether an "effective"  $\lambda$  will  
281 perform acceptably. Ct counts in Long et al. (2020) have a standard deviation  $\sim 4$ , representing an upper bound of a  
282 16-fold difference in viral load, because a difference of 1 Ct in PCR measures represents at most a 2-fold difference  
283 in underlying viral load, and because individuals are not sampled at exactly comparable times with respect to the  
284 timecourse of shedding. However, variance in dose from causes other than infectiousness, e.g. the intimacy of

285 contact, is not included. With a standard deviation representing a 16-fold difference, we find that by using a value  
286  $3/10^{\text{th}}$  of  $\lambda = 3.50 E - 06$ , we can super-impose the two curves up to 20% infection probability (Figure S2).  
287



288  
289 Figure S2. Although our dose-response curve takes the function of an expectation, for low infection probabilities the  
290 effect of this is to change the interpretation of the value of  $\lambda$ , which is  $3.50 \times 10^{-6}$  when using Eq. 5 but 0.3 times this  
291 value when using Eq.6 with a distribution of log-dose with standard deviation corresponding to a 16-fold difference  
292 in dose.

## 293 9.0 Transmission Risk Levels

294  
295 Transmission risk level in the GAEN API is a proxy for the magnitude of viral shedding and can be set by the app  
296 on the basis of a simple questionnaire administered to users reporting a positive diagnosis. We use this to inform  
297 expected shedding  $S$ .  
298

299 The first question we ask to inform transmission risk levels is, "What day did your symptoms start"? A curve fit to  
300 known transmission events suggests peak transmission the day before symptom onset, and essentially no  
301 transmission more than three days before symptom onset.<sup>43</sup> However, this might be confounded with behavioral  
302 changes with symptom onset, with ascertainment bias in terms of which transmission events are easiest to document,  
303 with onset of mild symptoms being overlooked and the later onset of more severe symptoms instead being reported,  
304 with possible errors in the direction of transmission given the variability of incubation periods, and with assumptions  
305 regarding the shape of the curve. Worse, the analysis appears to have significant technical flaws.<sup>4</sup>  
306

307 A second source of information is quantitative polymerase chain reaction (PCR). However, this may reflect non-  
308 infectious viral remnants, especially late in the course of disease, where the proportion of culture-positive PCR  
309 results tends to decrease.<sup>1,2</sup> However, this decline is also expected from a simple dose-response curve, where the  
310 probability of culture-positivity decreases as the amount of shedding decreases late in infection, i.e. the decline in  
311 infectivity might be quantitative rather than qualitative.  
312

313 While informed by the two sources of data above, we focus the most on data in which virus was successfully  
314 cultured from patient samples, as a clear indication of infectivity. Arons et al. <sup>2</sup> took prospective samples throughout  
315 a nursing home, and were able to culture virus from six days before symptom onset until nine days after symptom  
316 onset, with little quantitative trend in shedding rate conditional on a positive test. In hospitalized patients, Wölfel et  
317 al. <sup>3</sup> were unable to isolate live virus from cultures more than 8 days post symptom onset, despite PCR evidence of  
318 high shedding. In one case report, live virus has been isolated 18 days after symptom onset, but this seems to be an  
319 outlier.<sup>44</sup> Bullard et al. <sup>1</sup> quantified both TCID50 and PCR for 7 days post symptom onset, and saw an approximately  
320 10-fold decline in infectious dose. We note that culture methods may not be sensitive enough to capture low  
321 concentrations.<sup>2</sup> We nevertheless use this TCID50 data as motivation in assuming a 10-fold dynamic range in

322 shedding rates as a function of day relative to symptom onset. More studies measuring infectivity in a quantitative  
323 manner are needed, particularly in populations that represent a broader base of cases of varying ages and health  
324 status. Encouragingly, our settings based on culture data agreed with those from epidemiological modeling after  
325 corrections to the latter were made.<sup>4</sup> We slightly tweaked our settings for pre-symptomatic Transmission Risk  
326 Levels to agree with later epidemiological work.<sup>45</sup>  
327

328 A final source of information comes from detailed Taiwanese contact tracing<sup>46</sup>, who found a 1.0% symptomatic  
329 attack rate (95% CI 0.6-1.6%) for those exposed within five days of symptom onset, and 0% (95% CI 0–0.4%) for  
330 those exposed after. Risk from exclusively pre-symptomatic exposure was 0.7% (95% CI 0.2%-2.4%). German  
331 contact tracing also points to highest transmission risk around the time of symptom onset.<sup>47</sup>  
332

333 We use 6 of the 8 Transmission Risk Levels in the GAEN API to capture this range, evenly spaced on a log scale  
334 between 10 and 100 in arbitrary units, reserving the use of levels 7 and 8 for individuals for testing purposes and any  
335 future functionality. Transmission risk levels could also be manipulated for testing purposes, e.g. to help learn, if  
336 individuals voluntarily enter exposure details into a manual contact tracing database, how transmission risk varies in  
337 the real world, rather than just in TCID50 studies, as a function of a symptomatic status and time. We note that  
338 Transmission Risk Levels have been deprecated in the announced GAEN v1.5, and replaced with only two possible  
339 levels of infectiousness in v1.6. While the functionality of v1.1 should be preserved, we note that usage of  
340 Transmission Risk Levels would need to be standardized across different apps in order to ensure interoperability. In  
341 the description below, we outline not just our use of v1.1, but also the use we would make of six levels of  
342 infectiousness if they were to again be made available in a future API version. The assignments we use in this  
343 framework can of course be improved as more data become available. Our call for more than two levels of  
344 infectiousness comes from the fact that a systematic 10-fold difference in TCID50 has been observed, and that such  
345 a large difference seems to warrant more levels.  
346

347 Based on a holistic reading of the four sources of evidence described above, we assign the maximum level of 6 from  
348 one day pre-symptom onset to two days post-symptom onset. Five days before symptom onset we assign level 1,  
349 four days before we assign level 3, three days before level 4, and two days before level 5. Three days after symptom  
350 onset we assign level 5, four days after level 4, five days after level 3, 6-7 days after level 2, and 8-9 days after level  
351 1. Our termination at 9 days is based on current CDC guidance.<sup>9</sup>  
352

353 For users who report a positive test but no symptoms, there is likely a reason they were tested, and so we ask for the  
354 most likely day of exposure, if known. If provided, we assume that shedding did not begin until two days after  
355 exposure, at the earliest. We also ask for the date of sampling for the positive test (which can be reported by the  
356 healthcare provider rather than the app user) and assume peak shedding at around this time. Subject to the constraint  
357 from day of exposure, we assign Transmission Risk Level 3 to dates within with one day of the test, and level 2 to  
358 dates between 2 and 4 days of the test, although as discussed below, one study reports substantially longer shedding  
359 than these 9 days.<sup>8</sup> There is some evidence that viral shedding is lower in asymptomatic vs. symptomatic cases,<sup>48</sup>  
360 while another study indicates the shedding magnitudes may be similar.<sup>49</sup> Note that we assume that those with no  
361 symptoms at the time they receive a positive test result are asymptomatic rather than pre-symptomatic – should test  
362 turnaround times be sufficiently fast, it would be useful for users to be able to report symptom onset after the fact  
363 and trigger a change to previously reported Transmission Risk Levels, and we recommend that this functionality be  
364 added, together with restoring a greater number of Transmission Risk Levels, in future versions of the GAEN  
365 framework.

## 366 **10.0 Considerations in recommending and messaging variable quarantine durations**

367  
368 The need for consistent guidance to the public is an important consideration for implementing tailored risk scoring  
369 and modified quarantine recommendations. If for the sake of a consistency, a public health authority is not willing to  
370 authorize variable quarantine recommendations, as is currently the case in Arizona, but only 0 or 14 day quarantines  
371 from time of the last individually significant exposure, then the threshold for going into quarantine at all would need

372 to become more strict in order to maintain the same overall risk among the population under quarantine. In other  
373 words, retaining the same average probability of current or future infectiousness among the quarantined population  
374 would require some exposed individuals to no longer go into quarantine at all, in addition to others lengthening their  
375 quarantine out to 14 days. With a binary 0 or 14 day quarantine, the amount by which disease transmission is  
376 prevented per day of quarantine will be lower.

377  
378 Alternatively, to avoid mixed messaging regarding quarantine even while the app recommends quarantine of  
379 variable duration, one option is to suppress all details about individual exposures from the user's view, including  
380 their date. This has the additional advantage of decreasing the risk that users will be able to guess who exposed  
381 them, further preserving privacy.

382  
383 The app can communicate the risk of infectiousness either as a simple recommendation for which days to  
384 quarantine, or also as a quantitative score in order to "game-ify" the process of quarantine and give users positive  
385 feedback for each day they succeed in remaining at home until risk falls to a lower level. Further research is needed  
386 to assess the most effective messaging strategies. E.g., the app could display both current and projected risk of  
387 infectiousness on a simple scale of 1 to 10, so users can see how that risk will fall with each day of quarantine. This  
388 visualization might change perceptions. E.g., an individual who wants to comply with a 14-day quarantine, but does  
389 not feel able to, might rush out to get groceries before starting their quarantine in earnest, while shedding virus pre-  
390 symptomatically. Visualizing projected risk into the future would then give the message that if the exposed  
391 individual can only make do for one more day before leaving the home for essentials, that will help, because if they  
392 do not develop symptoms, their risk will be lower even after a single day longer. Risk communication in an app  
393 could focus on day to day coaxing of this form.

394  
395 Conflicting messages can still arise if manual contact tracers trace an individual who also received an exposure  
396 notification. In this case, it is likely that the two recommend different end dates for quarantine. While this is to be  
397 expected from our procedure for recommending variable quarantine durations, we note that even if the app were to  
398 issue 14 day quarantine recommendations only, it could still arise because the individual has been exposed more  
399 than once, on different days, and the manual contact tracer is following up an infected individual who may not have  
400 used the app. Until there is reliable data on app performance, we recommend that the manual contact tracer's  
401 protocol should override whatever the app says. Should the app turn out to perform well, an alternative procedure  
402 might eventually be to go with whichever protocol recommends the longer quarantine. An intermediate possibility is  
403 for the manual contact tracer to ask for exposure notification details, to determine whether it may be a different  
404 exposure to the one being manually traced. There may also be conflicts in protocols for the timing of testing.

405  
406 Note that with symptom onset sometimes as early as two days after exposure, and given the possibility of pre-  
407 symptomatic shedding, and the possibility of confusion regarding who infected whom, we currently ignore the  
408 possibility that shedding might not yet have begun. Current testing turnaround times are mostly long, making this  
409 reasonable. However, if same-day tests become more widely available, our approach could be extended to directly  
410 communicate the risk of current infectiousness, rather than as is currently the case, the risk of current or future  
411 infectiousness. A significantly lower risk of infectiousness will be present on the day of exposure and perhaps also  
412 the day after. Delays in going into public to prepare for a long quarantine could inadvertently lead to pushing  
413 individuals past the latent period before they go into public; displaying a full projected timeline of the projected risk  
414 of infectiousness could avert this, at the risk of significantly more complex messaging than "stay home until Friday".

415  
416 We currently consider the harm from the release of any infectious individual to be equivalent to that from the release  
417 of any other. Extensions of our approach could take into account greater harm from someone never quarantined and  
418 hence shedding for the full duration relative to someone released prematurely partway through asymptomatic or pre-  
419 symptomatic shedding, for whom a portion of the harm has already been mitigated. This would lead to steeper  
420 discounting and might also prevent the app from occasionally recommending quarantines of less than 5 days when  
421 initial risk is already very near the threshold.

## 422 References

- 423  
424 1 Bullard J, Dust K, Funk D, *et al.* Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect*  
425 *Dis* 2020; : 1–18.
- 426 2 Arons MM, Hatfield KM, Reddy SC, *et al.* Presymptomatic SARS-CoV-2 infections and transmission in a  
427 skilled nursing facility. *N Engl J Med* 2020; **382**: 2081–90.
- 428 3 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients with COVID-  
429 2019. *Nature* 2020; **581**: 465–9.
- 430 4 Ashcroft P, Huisman JS, Lehtinen S, *et al.* COVID-19 infectivity profile correction. *arXiv* 2020.  
431 <http://arxiv.org/abs/2007.06602>.
- 432 5 Curmei M, Ilyas A, Evans O, Steinhardt J. Estimating Household Transmission of SARS-CoV-2. *medRxiv*  
433 2020. DOI:10.1101/2020.05.23.20111559.
- 434 6 Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, *et al.* Asymptomatic SARS-CoV-2 infections: a living  
435 systematic review and meta-analysis, version 3. *medRxiv* 2020. DOI:10.1101/2020.04.25.20079103.
- 436 7 Lauer SA, Grantz KH, Bi Q, *et al.* The incubation period of coronavirus disease 2019 (CoVID-19) from  
437 publicly reported confirmed cases: Estimation and application. *Ann Intern Med* 2020; **172**: 577–82.
- 438 8 Long Q, Tang X, Shi Q, *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2  
439 infections. *Nat Med* 2020. DOI:10.1038/s41591-020-0965-6.
- 440 9 Centers for Disease Control and Prevention. Duration of Isolation & Precautions for Adults. 2020.  
441 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html#cecommendations> (accessed July  
442 27, 2020).
- 443 10 U.S. Environmental Protection Agency. Exposure Factors Handbook 2011 Edition (EPA/600/R-09/052F).  
444 Washington, DC, 2011 <https://cfpub.epa.gov/ncea/risk/recorddisplay.cfm?deid=236252>.
- 445 11 Leckie JO, Naylor KA, Canales RA, *et al.* Quantifying Children’s Microlevel Activity Data from Existing  
446 Videotapes” by Exposure Research Group at Stanford University for the U.S. Environmental Protection  
447 Agency. 2000  
448 [https://cfpub.epa.gov/ols/catalog/advanced\\_full\\_record.cfm?&FIELD1=AUTHOR&INPUT1=FERGUSON](https://cfpub.epa.gov/ols/catalog/advanced_full_record.cfm?&FIELD1=AUTHOR&INPUT1=FERGUSON)  
449 AND C. AND R.&TYPE1=ALL&LOGIC1=AND&COLL=&SORT\_TYPE=MTIC&item\_count=5.
- 450 12 Western Engineering. Self-study notes - GAUSSIAN PLUMES.  
451 [https://www.eng.uwo.ca/people/esavory/Gaussian plumes.pdf](https://www.eng.uwo.ca/people/esavory/Gaussian%20plumes.pdf) (accessed June 7, 2020).
- 452 13 Zhang N, Su B, Chan PT, Miao T, Wang P, Li Y. Infection spread and high-resolution detection of close  
453 contact behaviors. *Int J Environ Res Public Health* 2020; **17**. DOI:10.3390/ijerph17041445.
- 454 14 Farrell S, Leith DJ. Pairwise Handset Types and Orientations Are Sufficient to Blur Exposure Notification  
455 Thresholds. Trinity Coll. Dublin, Irel. 2020. <https://down.dsg.cs.tcd.ie/tact/posorient.pdf> (accessed Aug 6,  
456 2020).
- 457 15 Jain S, Islam T, Chowdhury B, Chen Y, Son Y. Agent-based simulation to evaluate various entrance and  
458 exit policies and contact-caused risks in classrooms under a pandemic situation. Univ. Arizona. .
- 459 16 Guo S, Yu J, Shi X, *et al.* Droplet-transmitted infection risk ranking based on close proximity interaction.  
460 *Front Neurobot* 2020; **13**: 1–11.
- 461 17 Setti L, Passarini F, De Gennaro G, *et al.* Airborne transmission route of covid-19: Why 2 meters/6 feet of  
462 inter-personal distance could not be enough. *Int J Environ Res Public Health* 2020; **17**.  
463 DOI:10.3390/ijerph17082932.
- 464 18 Chu DK, Akl EA, Duda S, *et al.* Physical distancing, face masks, and eye protection to prevent person-to-  
465 person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020; :  
466 1973–87.
- 467 19 Rea E, Laflèche J, Stalker S, *et al.* Duration and distance of exposure are important predictors of  
468 transmission among community contacts of Ontario SARS cases. *Epidemiol Infect* 2007; **135**: 914–21.
- 469 20 Salathé M, Kazandjieva M, Lee JW, Levis P, Feldman MW, Jones JH. A high-resolution human contact  
470 network for infectious disease transmission. *Proc Natl Acad Sci U S A* 2010; **107**: 22020–5.
- 471 21 Ma J, Qi X, Chen H, *et al.* Exhaled breath is a significant source of SARS-CoV-2 emission. *medRxiv* 2020; :  
472 2020.05.31.20115154.
- 473 22 Chen W, Zhang N, Wei J, Yen HL, Li Y. Short-range airborne route dominates exposure of respiratory  
474 infection during close contact. *Build Environ* 2020; **176**: 106859.
- 475 23 Brusca S, Famoso F, Lanzafame R, Mauro S, Garrano AMC, Monforte P. Theoretical and Experimental

- 476 Study of Gaussian Plume Model in Small Scale System. *Energy Procedia* 2016; **101**: 58–65.
- 477 24 Jang S, Han SH, Rhee J-Y. Cluster of Coronavirus Disease Associated with Fitness Dance Classes, South  
478 Korea. *Emerg Infect Dis* 2020; **26**. DOI:10.3201/eid2608.200633.
- 479 25 Yang W, Elankumaran S, Marr LC. Concentrations and size distributions of airborne influenza A viruses  
480 measured indoors at a health centre, a day-care centre and on aeroplanes. *J R Soc Interface* 2011; **8**: 1176–  
481 84.
- 482 26 Feng Y, Marchal T, Sperry T, Yi H. Influence of wind and relative humidity on the social distancing  
483 effectiveness to prevent COVID-19 airborne transmission : A numerical study. *J Aerosol Sci* 2020; **147**:  
484 105585.
- 485 27 Qureshi Z, Jones N, Temple R, Larwood JP, Greenhalgh T, Bourouiba L. What is the evidence to support  
486 the 2-metre social distancing rule to reduce COVID-19 transmission? CEBM. 2020.  
487 [https://www.cebm.net/covid-19/what-is-the-evidence-to-support-the-2-metre-social-distancing-rule-to-](https://www.cebm.net/covid-19/what-is-the-evidence-to-support-the-2-metre-social-distancing-rule-to-reduce-covid-19-transmission/)  
488 [reduce-covid-19-transmission/](https://www.cebm.net/covid-19/what-is-the-evidence-to-support-the-2-metre-social-distancing-rule-to-reduce-covid-19-transmission/) (accessed July 15, 2020).
- 489 28 Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. *Science (80- )* 2020; **368**.
- 490 29 Lednicky JA, Lauzardo M, Fan ZH, *et al*. Viable SARS-CoV-2 in the air of a hospital room with COVID-19  
491 patients. *medRxiv* 2020. DOI:10.1101/2020.08.03.20167395.
- 492 30 Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *Lancet Respir Med*  
493 2020; **2600**: 1–11.
- 494 31 Jones NR, Qureshi ZU, Temple RJ, Larwood JPJ, Greenhalgh T, Bourouiba L. Two metres or one: what is  
495 the evidence for physical distancing in covid-19? *BMJ* 2020; **370**: m3223.
- 496 32 Wei Y, Wei L, Liu Y, Huang L, Shen S, Zhang R. A systematic review and meta-analysis reveals long and  
497 dispersive incubation period of COVID-19. *medRxiv* 2020.
- 498 33 Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and  
499 control of COVID-19 epidemics. *medRxiv* 2020; : 2020.03.24.20043018.
- 500 34 Chen X, Zhang Y, Zhu B, *et al*. Associations of Clinical Characteristics and Antiviral Drugs with Viral  
501 RNA Clearance in Patients with COVID-19 in Guangzhou, China. *medRxiv* 2020.  
502 DOI:10.2139/ssrn.3566234.
- 503 35 Chau NVV, Thanh Lam V, Thanh Dung N, *et al*. The natural history and transmission potential of  
504 asymptomatic SARS-CoV-2 infection. *Clin Infect Dis* 2020; **0813**: 1–30.
- 505 36 Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs  
506 Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw open* 2020; **3**: e2010182.
- 507 37 Xiao T, Wang Y, Yuan J, *et al*. Early viral clearance and antibody kinetics of COVID-19 among  
508 asymptomatic carriers. *medRxiv* 2020. DOI:10.1101/2020.04.28.20083139.
- 509 38 Hu Z, Song C, Xu C, *et al*. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened  
510 among close contacts in Nanjing, China. *Sci China Life Sci* 2020; **63**: 706–11.
- 511 39 Ottino-Loffler B, Scott JG, Strogatz SH. Evolutionary dynamics of incubation periods. *Elife* 2017; **6**.  
512 DOI:10.7554/eLife.30212.
- 513 40 Yang Y, Yang M, Shen C, *et al*. Evaluating the accuracy of different respiratory specimens in the laboratory  
514 diagnosis and monitoring the viral shedding of 2019-nCoV infections. *medRxiv* 2020; :  
515 2020.02.11.20021493.
- 516 41 Ai T, Yang Z, Hou H, *et al*. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019  
517 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020; **2019**: 200642.
- 518 42 Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse  
519 Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Ann Intern  
520 Med* 2020. DOI:10.7326/m20-1495.
- 521 43 He X, Lau EHY, Wu P, *et al*. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat  
522 Med* 2020; **26**: 672–5.
- 523 44 Liu W Da, Chang SY, Wang JT, *et al*. Prolonged virus shedding even after seroconversion in a patient with  
524 COVID-19. *J Infect* 2020. DOI:10.1016/j.jinf.2020.03.063.
- 525 45 Ferretti L, Ledda A, Wymant C, *et al*. The timing of COVID-19 transmission. *medRxiv* 2020.  
526 DOI:10.1101/2020.09.04.20188516.
- 527 46 Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact Tracing Assessment of COVID-19  
528 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods before and after Symptom Onset.  
529 *JAMA Intern Med* 2020. DOI:10.1001/jamainternmed.2020.2020.
- 530 47 Böhmer MM, Buchholz U, Corman VM, *et al*. Investigation of a COVID-19 outbreak in Germany resulting

- 531 from a single travel-associated primary case: a case series. *Lancet Infect Dis* 2020; **3099**.  
532 DOI:10.1016/S1473-3099(20)30314-5.  
533 48 McDonald J. Unpacking WHO's Asymptomatic COVID-19 Transmission Comments. FactCheck.org. 2020.  
534 <https://www.factcheck.org/2020/06/unpacking-whos-asymptomatic-covid-19-transmission-comments/>  
535 (accessed June 16, 2020).  
536 49 Lavezzo E, Franchin E, Ciavarella C, *et al.* Suppression of a SARS-CoV-2 outbreak in the Italian  
537 municipality of Vo'. *Nature* 2020; published online June 30. DOI:10.1038/s41586-020-2488-1.  
538